Back to Search
Start Over
Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors.
- Source :
- Acta Psychiatrica Scandinavica; Dec2002 Supplement, Vol. 106, p24-30, 0p
- Publication Year :
- 2002
-
Abstract
- Objective: To evaluate data supporting the ability of venlafaxine, an antidepressant with a dual mechanism of action, to produce remission from depression. Method: Review of multicentre, double-blind, randomized studies comparing venlafaxine or venlafaxine extended release (XR) with a selective serotonin reuptake inhibitor (SSRI), using Hamilton Depression Rating Scale total scores in the range of ≤7 and <10 as the final outcome measure, to evaluate the ability of venlafaxine/venlafaxine XR to produce full remission from depression. Results: Venlafaxine/venlafaxine XR demonstrated higher rates of remission than did the SSRIs and placebo. Conclusion: With full remission rather than response as the measure of outcome, venlafaxine/venlafaxine XR demonstrated more robust antidepressant efficacy than the SSRIs and placebo. This finding suggests that venlafaxine/venlafaxine XR are appropriate standard-of-care therapies for the treatment of patients with major depressive disorder. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0001690X
- Volume :
- 106
- Database :
- Complementary Index
- Journal :
- Acta Psychiatrica Scandinavica
- Publication Type :
- Academic Journal
- Accession number :
- 63184243
- Full Text :
- https://doi.org/10.1034/j.1600-0447.106.s415.5.x